Notas de Prensa
-
2020-09-10DD MM YYYYPDFLa vacunación como protección a lo largo de la vida
-
2020-09-10DD MM YYYYPDFEl New England Journal of Medicine publica los resultados finales positivos del estudio de fase 12a de BIVV001 en personas con hemofilia A grave
-
2020-09-10DD MM YYYYPDFDupixent® (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-tosevere asthma
-
2020-09-09DD MM YYYYPDFLíderes de biofarma se unen para defender la ciencia
-
-
-
2020-05-25DD MM YYYYPDFSanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration
-
2020-04-24DD MM YYYYPDFFDA approves MenQuadfiTM, the latest innovation in meningococcal (MenACWY) vaccination
-
2020-04-14DD MM YYYYPDFSanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
-
2020-04-06DD MM YYYYPDFSanofi successfully prices taps on outstanding bond issues for EUR 500 million
-
2020-04-03DD MM YYYYPDFDupixent<sup>®</sup> (dupilumab) Phase 3 data show significant improvement in severe atopic dermatitis for children aged 6 to 11 years
-
2020-04-03DD MM YYYYPDFAvailability of the Pre-quarterly Results Communication
-
2020-03-27DD MM YYYYPDFSanofi receives positive CHMP opinion for Sarclisa<sup>®</sup> (isatuximab) for the treatment of relapsed and refractory multiple myeloma
-
2020-03-27DD MM YYYYPDFSanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19
-
2020-03-02DD MM YYYYPDFFDA approves Sarclisa<sup>®</sup> (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
-
2020-02-24DD MM YYYYPDFSanofi to create new industry leading European company to provide active pharmaceutical ingredients (API)
-
2020-01-28DD MM YYYYPDFFDA accepts for priority review Dupixent<sup>®</sup> (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis